Nanotherapix

Nanotherapix has created a platform to produce autologous therapies for autoimmune and chronic inflammatory diseases, and is ready to start a PoC in MS

  • Stage Product In Development
  • Industry Biotechnology
  • Location Barcelona, Spain
  • Currency EUR
  • Founded June 2009
  • Employees 3
  • Incorporation Type Other
  • Website none

Company Summary

Nanotherapix has developed a platform for ex vivo reprogramming of peripheral blood cells (NT-cells) which upon i.v. administration are able to address to inflammed sites and home there. NT-cells can steadily express a selected therapeutic gene for long periods of time. NT-cell technology is applicable to human monocytes. Readministration is feasible since NT-cells do not raise immune response.

Team

  • Jordi Cabot Suñol
    Business Development

    - Former Head of New Projects & Market Research Almirall
    - IESE MBA
    - Industrial Engineering ETSEIB UPC

  • Miguel Chillón
    Founder

    - ICREA Researcher
    - Head of research group at Vall d’Hebron Research Institute (VHIR)
    - Head of Unitat Mixta UAB-VHIR
    - Director of the technological platform: Vector Production Unit UPV
    - Vice-Chair EATRIS-ERIC; European Infrastructure for Translational Medicine

  • Ester Fernández
    Founder

    - Professor of Physiology, Universitat Autònoma de Barcelona
    - Leader of Grup de Recerca en Inflamació i Tolerància
    - Senior Investigator Institut de Neurociències, UAB
    - Senior Investigator CIBER-ehd

  • Miquel Àngel Gassull
    Founder

    - Professor of Gastroenterology, Universitat Autònoma de Barcelona
    - Former Chairman of Dept of Gastroenterology and Hepatology. Hospital Universitari Germans Trias i Pujol
    - Former Director of the Health Sciences Resarch Insitute. Germans Trias i Pujol Foundation
    - Founder and Former President of the European Crohn’s and Colitis Organization (ECCO)
    - Editor- in Chief of the Journals Clinical Nutrition and Journal of Crohn’s and Colitis

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free